In addition to SRF and nexilin, many of the other YAP/TAZ–TEAD targets were likewise downregulated in atherosclerosis datasets, reinforcing the notion that YAP/TAZ deficiency recapitulates disease-associated transcriptional reprogramming. This evidence concerns the gene SRF and atherosclerosis.